News

Impax EVP finance, CFO resigns

BY Alaric DeArment

HAYWARD, Calif. — One of Impax Labs’ top executives is leaving the company, the drug maker announced Friday.

Impax said EVP finance and CFO Arthur Koch would resign to pursue other opportunities. VP finance Bryan Reasons has been appointed acting CFO as the company searches for a successor to Koch.

"During the past seven years that Arthur Koch has been with us, the company has grown tremendously, and I deeply appreciate his service to the company," president and CEO Larry Hsu said. "Bryan Reasons is an able and experienced financial executive who will be the interim CFO, reporting to me, as we conduct an external search for a permanent CFO."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Gilead seeks approval for HIV drug-boosting agent

BY Alaric DeArment

FOSTER CITY, Calif. — Drug maker Gilead Sciences has submitted a regulatory approval application to the Food and Drug Administration for a drug designed to increase the blood levels of certain drugs for HIV.

The company said Thursday it had submitted an application for cobicistat, a "boosting" agent that works with some HIV drugs — specifically Johnson & Johnson’s Prezista (darunavir) and Bristol-Myers Squibb’s Reyataz (atazanavir) — to enable once-daily dosing. The drug also is a component of Gilead’s HIV treatment Quad (cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil fumarate).

The regulatory filing was based on data from a 48-week, phase-3 study in which cobicistat was shown to work as well as Abbott’s Norvir (ritonavir) when combined with Reyataz and Gilead’s Truvada (emtricitabine and tenofovir disoproxil fumarate).


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Fuse Science’s EnerJel to enter GNC stores this summer

BY Allison Cerra

MIAMI LAKES, Fla. — Fuse Science is distributing its EnerJel product through GNC stores nationwide, the company announced.

EnerJel, an all-natural, performance-driven product, is expected to hit store shelves in mid-July.

"We are excited to join forces with GNC to expand distribution of our EnerJel product," Fuse Science president and COO Rubin Hanan said. "Our new displays, which feature David Ortiz, Arian Foster and Ronde Barber, clearly set us apart at retail as they showcase the EnerJel heat zones for best usage of the product. Once consumers try EnerJel on their aches and pains, and engage in the pre-game ritual to raise their game, we are confident expectations will be exceeded and people will know what it means to be Powered By Fuse just like some of the world’s best athletes."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?